{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:08:22Z","timestamp":1751360902798,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:00:00Z","timestamp":1660953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:00:00Z","timestamp":1660953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["P1-0189","P1-0153"],"award-info":[{"award-number":["P1-0189","P1-0153"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s00280-022-04465-9","type":"journal-article","created":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T05:02:50Z","timestamp":1660971770000},"page":"301-313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Population pharmacokinetics of cisplatin in small cell lung cancer patients guided with informative priors"],"prefix":"10.1007","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8680-3792","authenticated-orcid":false,"given":"Jurij","family":"Aguiar Zdovc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihaela","family":"Vaupoti\u010d","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Marolt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7743-2827","authenticated-orcid":false,"given":"Lea","family":"Knez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Re\u017eonja Kukec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4417-7161","authenticated-orcid":false,"given":"Tanja","family":"\u010cufer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3322-4807","authenticated-orcid":false,"given":"Toma\u017e","family":"Vovk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3452-1499","authenticated-orcid":false,"given":"Iztok","family":"Grabnar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,20]]},"reference":[{"key":"4465_CR1","doi-asserted-by":"crossref","unstructured":"American Cancer Society (2021) Cancer Facts & Figures 2021.\u00a0https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2021\/cancer-facts-and-figures-2021.pdf. Accessed 18 May 2022","DOI":"10.4324\/9781003138594-2"},{"key":"4465_CR2","unstructured":"European Medicines Agency (2020) Guideline on the clinical evaluation of anticancer medicinal products.\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-evaluation-anticancer-medicinal-products-man-revision-6_en.pdf. Accessed 18 May 2022"},{"key":"4465_CR3","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2001.19.17.3733","volume":"19","author":"FE De Jongh","year":"2001","unstructured":"De Jongh FE, Verweij J, Loos WJ et al (2001) Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 19:3733\u20133739. https:\/\/doi.org\/10.1200\/JCO.2001.19.17.3733","journal-title":"J Clin Oncol"},{"key":"4465_CR4","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1038\/sj.bjc.6600139","volume":"86","author":"H Gurney","year":"2002","unstructured":"Gurney H (2002) How to calculate the dose of chemotherapy. Br J Cancer 86:1297\u20131302. https:\/\/doi.org\/10.1038\/sj.bjc.6600139","journal-title":"Br J Cancer"},{"key":"4465_CR5","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/bjc.2012.357","volume":"107","author":"E Chatelut","year":"2012","unstructured":"Chatelut E, White-Koning ML, Mathijssen RH et al (2012) Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. Br J Cancer 107:1100\u20131106. https:\/\/doi.org\/10.1038\/bjc.2012.357","journal-title":"Br J Cancer"},{"key":"4465_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"4465_CR7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","volume":"32","author":"A-MC Dingemans","year":"2021","unstructured":"Dingemans A-MC, Fr\u00fch M, Ardizzoni A et al (2021) Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2606. Ann Oncol 32:839\u2013853. https:\/\/doi.org\/10.1016\/j.annonc.2021.03.207","journal-title":"Ann Oncol"},{"key":"4465_CR8","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","volume":"18","author":"C Faivre-Finn","year":"2017","unstructured":"Faivre-Finn C, Snee M, Ashcroft L et al (2017) Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol 18:1116\u20131125. https:\/\/doi.org\/10.1016\/S1470-2045(17)30318-2","journal-title":"Lancet Oncol"},{"key":"4465_CR9","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y et al (2019) Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394:1929\u20131939. https:\/\/doi.org\/10.1016\/S0140-6736(19)32222-6","journal-title":"Lancet"},{"key":"4465_CR10","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00280-013-2288-5","volume":"72","author":"R Chen","year":"2013","unstructured":"Chen R, Li J, Hu WW et al (2013) Circadian variability of pharmacokinetics of cisplatin in patients with non-small-cell lung carcinoma: analysis with the NONMEM program. Cancer Chemother Pharmacol 72:1111\u20131123. https:\/\/doi.org\/10.1007\/s00280-013-2288-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"4465_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00280-004-0790-5","volume":"54","author":"FE de Jongh","year":"2004","unstructured":"de Jongh FE, Gallo JM, Shen M et al (2004) Population pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemother Pharmacol 54:105\u2013112. https:\/\/doi.org\/10.1007\/s00280-004-0790-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"4465_CR12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00280-020-04147-4","volume":"86","author":"T Morita-Ogawa","year":"2020","unstructured":"Morita-Ogawa T, Sugita H, Minami H et al (2020) Population pharmacokinetics and renal toxicity of cisplatin in cancer patients with renal dysfunction. Cancer Chemother Pharmacol 86:559\u2013566. https:\/\/doi.org\/10.1007\/s00280-020-04147-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"4465_CR13","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1177\/009127009803801107","volume":"38","author":"N Nagai","year":"1998","unstructured":"Nagai N, Ogata H, Wada Y et al (1998) Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program. J Clin Pharmacol 38:1025\u20131034","journal-title":"J Clin Pharmacol"},{"key":"4465_CR14","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/j.1365-2125.2004.02082.x","volume":"57","author":"S Urien","year":"2004","unstructured":"Urien S, Lokiec F (2004) Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol 57:756\u2013763. https:\/\/doi.org\/10.1111\/j.1365-2125.2004.02082.x","journal-title":"Br J Clin Pharmacol"},{"key":"4465_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00280-004-0852-8","volume":"55","author":"S Urien","year":"2005","unstructured":"Urien S, Brain E, Bugat R et al (2005) Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients. Cancer Chemother Pharmacol 55:55\u201360. https:\/\/doi.org\/10.1007\/s00280-004-0852-8","journal-title":"Cancer Chemother Pharmacol"},{"key":"4465_CR16","doi-asserted-by":"publisher","first-page":"S1512","DOI":"10.21037\/tcr.2017.09.14","volume":"6","author":"AS Darwich","year":"2017","unstructured":"Darwich AS, Ogungbenr K, Hatley OJ, Rostami-Hodjegan A (2017) Role of pharmacokinetic modeling and simulation in precision dosing of anticancer drugs. Transl Cancer Res 6:S1512\u2013S1529. https:\/\/doi.org\/10.21037\/tcr.2017.09.14","journal-title":"Transl Cancer Res"},{"key":"4465_CR17","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/JCO.2005.03.0056","volume":"24","author":"WJ Loos","year":"2006","unstructured":"Loos WJ, De Jongh FE, Sparreboom A et al (2006) Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J Clin Oncol 24:1499\u20131506. https:\/\/doi.org\/10.1200\/JCO.2005.03.0056","journal-title":"J Clin Oncol"},{"key":"4465_CR18","first-page":"465","volume":"34","author":"F Puisset","year":"2014","unstructured":"Puisset F, Schmitt A, Chatelut E (2014) Standardization of chemotherapy and individual dosing of platinum compounds. Anticancer Res 34:465\u2013470","journal-title":"Anticancer Res"},{"key":"4465_CR19","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/bjc.1996.296","volume":"73","author":"JHM Schellens","year":"1996","unstructured":"Schellens JHM, Ma J, Planting AST et al (1996) Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer 73:1569\u20131575. https:\/\/doi.org\/10.1038\/bjc.1996.296","journal-title":"Br J Cancer"},{"key":"4465_CR20","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage:prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748\u20131756. https:\/\/doi.org\/10.1200\/JCO.1989.7.11.1748","journal-title":"J Clin Oncol"},{"key":"4465_CR21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s40265-018-0909-3","volume":"78","author":"PM Kasi","year":"2018","unstructured":"Kasi PM, Grothey A (2018) Chemotherapy-induced neutropenia as a prognostic and predictive marker of outcomes in solid-tumor patients. Drugs 78:737\u2013745. https:\/\/doi.org\/10.1007\/s40265-018-0909-3","journal-title":"Drugs"},{"key":"4465_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.annonc.2019.11.001","volume":"31","author":"PM Kasi","year":"2020","unstructured":"Kasi PM, Grothey A (2020) Should we optimize cytotoxic therapy by dosing to neutropenia? Lessons from TAS-102. Ann Oncol 31:15\u201316. https:\/\/doi.org\/10.1016\/j.annonc.2019.11.001","journal-title":"Ann Oncol"},{"key":"4465_CR23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.annonc.2019.10.005","volume":"31","author":"T Yoshino","year":"2020","unstructured":"Yoshino T, Cleary JM, Van Cutsem E et al (2020) Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine\/tipiracil in the RECOURSE and J003 trials. Ann Oncol 31:88\u201395. https:\/\/doi.org\/10.1016\/j.annonc.2019.10.005","journal-title":"Ann Oncol"},{"key":"4465_CR24","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(05)70255-2","volume":"6","author":"M Di Maio","year":"2005","unstructured":"Di Maio M, Gridelli C, Gallo C et al (2005) Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 6:669\u2013677. https:\/\/doi.org\/10.1016\/S1470-2045(05)70255-2","journal-title":"Lancet Oncol"},{"key":"4465_CR25","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1111\/bcp.14360","volume":"86","author":"R ter Heine","year":"2020","unstructured":"ter Heine R, Keizer RJ, van Steeg K et al (2020) Prospective validation of a model-informed precision dosing tool for vancomycin in intensive care patients. Br J Clin Pharmacol 86:2497\u20132506. https:\/\/doi.org\/10.1111\/bcp.14360","journal-title":"Br J Clin Pharmacol"},{"key":"4465_CR26","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/j.1365-2125.2012.04406.x","volume":"75","author":"W Zhao","year":"2013","unstructured":"Zhao W, Kaguelidou F, Biran V et al (2013) External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. Br J Clin Pharmacol 75:1068\u20131080. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04406.x","journal-title":"Br J Clin Pharmacol"},{"key":"4465_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.02543-18","volume":"63","author":"T Guo","year":"2019","unstructured":"Guo T, van Hest RM, Roggeveen LF et al (2019) External evaluation of population pharmacokinetic models of vancomycin in large cohorts of intensive care unit patients. Antimicrob Agents Chemother 63:1\u20139. https:\/\/doi.org\/10.1128\/AAC.02543-18","journal-title":"Antimicrob Agents Chemother"},{"key":"4465_CR28","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s13318-021-00681-5","volume":"46","author":"A Chan Kwong","year":"2021","unstructured":"Chan Kwong A, O\u2019Jeanson A, Khier S (2021) Model-informed therapeutic drug monitoring of meropenem in critically Ill patients: improvement of the predictive ability of literature models with the PRIOR approach. Eur J Drug Metab Pharmacokinet 46:415\u2013426. https:\/\/doi.org\/10.1007\/s13318-021-00681-5","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"4465_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10928-020-09695-z","volume":"47","author":"AHXP Chan Kwong","year":"2020","unstructured":"Chan Kwong AHXP, Calvier EAM, Fabre D et al (2020) Prior information for population pharmacokinetic and pharmacokinetic\/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine. J Pharmacokinet Pharmacodyn 47:431\u2013446. https:\/\/doi.org\/10.1007\/s10928-020-09695-z","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"4465_CR30","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1054\/bjoc.2000.1643","volume":"84","author":"JG Wright","year":"2001","unstructured":"Wright JG, Boddy AV, Highley M et al (2001) Estimation of glomerular filtration rate in cancer patients. BrJCancer 84:452\u2013459. https:\/\/doi.org\/10.1054\/bjoc.2000.1643","journal-title":"BrJCancer"},{"key":"4465_CR31","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","volume":"317","author":"RD Mosteller","year":"1987","unstructured":"Mosteller RD (1987) Simplified calculation of body-surface area. N Engl J Med 317:1098\u20131098. https:\/\/doi.org\/10.1056\/NEJM198710223171717","journal-title":"N Engl J Med"},{"key":"4465_CR32","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1023\/a:1022972420004","volume":"29","author":"PO Gisleskog","year":"2002","unstructured":"Gisleskog PO, Karlsson MO, Beal SL (2002) Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn 29:473\u2013505. https:\/\/doi.org\/10.1023\/a:1022972420004","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"4465_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/2017SW001669","volume":"16","author":"SK Morley","year":"2018","unstructured":"Morley SK, Brito TV, Welling DT (2018) Measures of model performance based on the log accuracy ratio. Sp Weather 16:69\u201388. https:\/\/doi.org\/10.1002\/2017SW001669","journal-title":"Sp Weather"},{"key":"4465_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13091368","author":"C Schr\u00e4pel","year":"2021","unstructured":"Schr\u00e4pel C, Kovar L, Selzer D et al (2021) External model performance evaluation of twelve infliximab population pharmacokinetic models in patients with inflammatory bowel disease. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics13091368","journal-title":"Pharmaceutics"},{"key":"4465_CR35","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1002\/psp4.12720","volume":"10","author":"PO Hanafin","year":"2021","unstructured":"Hanafin PO, Nation RL, Scheetz MH et al (2021) Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients. CPT pharmacometrics Syst Pharmacol 10:1525\u20131537. https:\/\/doi.org\/10.1002\/psp4.12720","journal-title":"CPT pharmacometrics Syst Pharmacol"},{"key":"4465_CR36","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3390\/pharmaceutics13081191","volume":"13","author":"C Konecki","year":"2021","unstructured":"Konecki C, Feliu C, Cazaubon Y et al (2021) External evaluation of population pharmacokinetic models and Bayes-based dosing of infliximab. Pharmaceutics 13:1191. https:\/\/doi.org\/10.3390\/pharmaceutics13081191","journal-title":"Pharmaceutics"},{"key":"4465_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15122","author":"\u00c1 Corral Alaejos","year":"2021","unstructured":"Corral Alaejos \u00c1, Zarzuelo Casta\u00f1eda A, Jim\u00e9nez Cabrera S et al (2021) External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia. Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/bcp.15122","journal-title":"Br J Clin Pharmacol"},{"key":"4465_CR38","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/bjc.2016.439","volume":"116","author":"C Faivre","year":"2017","unstructured":"Faivre C, El Cheikh R, Barbolosi D, Barlesi F (2017) Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients. Br J Cancer 116:344\u2013348. https:\/\/doi.org\/10.1038\/bjc.2016.439","journal-title":"Br J Cancer"},{"key":"4465_CR39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejca.2021.10.010","volume":"160","author":"N Chargi","year":"2022","unstructured":"Chargi N, Molenaar-Kuijsten L, Huiskamp LFJ et al (2022) The association of cisplatin pharmacokinetics and skeletal muscle mass in patients with head and neck cancer: the prospective PLATISMA study. Eur J Cancer 160:92\u201399. https:\/\/doi.org\/10.1016\/j.ejca.2021.10.010","journal-title":"Eur J Cancer"},{"key":"4465_CR40","first-page":"1037","volume":"48","author":"Y Nakazawa","year":"2021","unstructured":"Nakazawa Y, Kageyama A, Kitamura M et al (2021) Prediction of severe cisplatin-induced neutropenia using serum albumin concentration-a retrospective study. Gan To Kagaku Ryoho 48:1037\u20131042","journal-title":"Gan To Kagaku Ryoho"},{"key":"4465_CR41","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1691\/ph.2018.7902","volume":"73","author":"S Kawachi","year":"2018","unstructured":"Kawachi S, Shinoda Y, Kimura M et al (2018) Risk factors for severe neutropenia induced by combination therapy of S-1 and cisplatin in patients with advanced\/recurrent gastric cancer. Pharmazie 73:174\u2013177. https:\/\/doi.org\/10.1691\/ph.2018.7902","journal-title":"Pharmazie"},{"key":"4465_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2020.00172","volume":"11","author":"D Alihodzic","year":"2020","unstructured":"Alihodzic D, Broeker A, Baehr M et al (2020) Impact of inaccurate documentation of sampling and infusion time in model-informed precision dosing. Front Pharmacol 11:1\u201312. https:\/\/doi.org\/10.3389\/fphar.2020.00172","journal-title":"Front Pharmacol"},{"key":"4465_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz420.008","author":"H Ishikawa","year":"2019","unstructured":"Ishikawa H, Tsuji D, Miyagi T et al (2019) Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdz420.008","journal-title":"Ann Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04465-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-022-04465-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04465-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T15:52:59Z","timestamp":1664985179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-022-04465-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,20]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["4465"],"URL":"https:\/\/doi.org\/10.1007\/s00280-022-04465-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2022,8,20]]},"assertion":[{"value":"18 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no personal or financial conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Slovenian Ethics Committee for Research in Medicine (KME 0120-220\/2018\/3).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}